1. Market Research
About 400 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Pharmaceuticals, Biopharmaceuticals, Generics and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 325412

  • $ 1995
  • November 2018
  • 82 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • United States
  • Company Financials

Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 325400

  • $ 1995
  • November 2018
  • 87 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • United States
  • Company Financials

Chemicals Manufacturing, Including Basic, Specialty, Petrochemicals, Pharmaceuticals, Soaps and Paints, Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 325000

  • $ 1995
  • November 2018
  • 93 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • United States
  • Company Financials

Companion to The Almanac of American Employers 2019: Market Research, Statistics and Trends Pertaining to America’s Hottest Mid-Size Employers

  • $ 380
  • March 2019
  • 624 pages

ADCETRIS (brentuximab vedotin) is approved in more than ## countries, and indicated for treatment of patients with classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

  • Lymphoma
  • United States
  • Company

Almanac of Middle Market Companies 2020: Middle Market Industry Market Research, Statistics, Trends and Leading Companies

  • $ 380
  • July 2019
  • 638 pages

Food and Drug Administration and the European Commission for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma (sALCL), as well as for certain types of cutaneous T-cell lymphoma (CTCL).

  • Lymphoma
  • United States
  • Company

Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 621511

  • $ 1995
  • November 2018
  • 66 pages

These centers cover fields of medical research and analysis such as hematology and genetics examination; women' s health; diagnoses of biopsy specimens for urologic pathology and renal diseases; diagnostic tests and diseases management for leukemia, lymphoma and cancers of the breast, p

  • Laboratory
  • Lymphoma
  • United States
  • Company Financials
  • Quest Diagnostics Incorporated

Medical and Diagnostic Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 621500

  • $ 1995
  • November 2018
  • 66 pages

These centers cover fields of medical research and analysis such as hematology and genetics examination; women' s health; diagnoses of biopsy specimens for urologic pathology and renal diseases; diagnostic tests and diseases management for leukemia, lymphoma and cancers of the breast, p

  • Laboratory
  • Lymphoma
  • United States
  • Company Financials
  • Quest Diagnostics Incorporated

Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 325411

  • $ 1995
  • November 2018
  • 67 pages

lymphoma kinase, or ALK, inhibitor (targeted anti-cancer agent) currently in preclinical development.

  • Lymphoma
  • United States
  • Company Financials
  • Balchem Corporation

Engineering & Research Industry Almanac 2019: Engineering & Research Industry Market Research, Statistics, Trends and Leading Companies

  • $ 380
  • May 2019
  • 666 pages

Its Yescarta cell therapy is FDA- and EC-approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • North America
  • United States
  • Company

Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2025, NAIC 325414

  • $ 1995
  • November 2018
  • 67 pages

Analytics, Extensive Financial Benchmarks, Metrics and Vaccines, Skin Replacement Products and Biologicals Revenue Forecasts to 2025, NAIC ## Manufacturing Industry (U. S. )

  • Lymphoma
  • Therapy
  • United States
  • Company Financials
  • Zoetis Inc.

Pharmaceuticals Market USA Sep 2017

  • $ 1995
  • September 2017
  • 59 pages

Plunkett-Netscribes Research Insert Cover Image using Slide Master View Do not change the aspect ratio or distort the image.

  • Lymphoma
  • Pharmaceutical
  • United States
  • Market Size
  • Bristol-Myers Squibb Company

Renewable Energy Group Inc (REGI:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

  • $ 1995
  • August 2017
  • 84 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • United States
  • Company Financials
  • Renewable Energy Group, Inc.

Titan Pharmaceuticals Inc (TTNP:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

  • $ 1995
  • August 2017
  • 84 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • United States
  • Company Financials
  • Titan Pharmaceuticals, Inc.

Advertising & Branding Industry Almanac 2019: Advertising & Branding Industry Market Research, Statistics, Trends and Leading Companies

  • $ 380
  • April 2019
  • 463 pages

Epsilon' s customers have included Walgreens, Dunkin' Donuts, Cabela' s, ##, Norwegian Cruise Line, DELL, BP, Cracker Barrel, Hormel Foods, BeachBody, Just Fab, Nature' s Way, Leukemia & Lymphoma Society, Rhone, The Humane Society, Healthy Directions, The Nature Conser

  • Advertising And Marketing
  • Lymphoma
  • Marketing
  • Media And Entertainment
  • Company

The Almanac of American Employers 2019: Market Research, Statistics and Trends Pertaining to the Leading Corporate Employers in America

  • $ 380
  • September 2018
  • 624 pages

In addition, the company has certain business and financial rights with respect to: RITUXAN for the treatment of non- Hodgkin' s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of prima

  • Lymphoma
  • Company

Kronos Worldwide Inc (KRO:NYS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

  • $ 1995
  • August 2017
  • 84 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • United States
  • Company Financials
  • Kronos Incorporated

Ashland Global Holdings Inc (ASH:NYS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

  • $ 1995
  • August 2017
  • 84 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • United States
  • Company Financials
  • Ashland Inc.

Plunkett’s Companion to The Almanac of American Employers 2018: Market Research, Statistics & Trends Pertaining to America’s Hottest Mid-size Employers

  • $ 380
  • March 2018
  • 615 pages

In this pipeline, there are seven different trials utilizing the Imbruvica inhibitor, in phases ##, ## or ##, for the treatment of diffusing large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphoblastic leuke

  • Lymphoma
  • Company

Manufacturing, Automation & Robotics Industry Almanac 2019: Manufacturing, Automation & Robotics Industry Market Research, Statistics, Trends and Leading Companies

  • $ 380
  • August 2018
  • 687 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Automotive
  • Lymphoma
  • Manufacturing
  • Company

Engineering & Research Industry Market Research, Statistics, Trends & Leading Companies 2018

  • $ 380
  • May 2018
  • 680 pages

Its Yescarta cell therapy was recently approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

  • Lymphoma
  • Company
View report >

Lymphoma Statistics in the UK

  • January 2018
  • 6 pages

(observed and ##. ##% five years from a lymphoma diagnosis in 2009-2013.

  • Cancer
  • Lymphoma
  • United Kingdom
  • Demographic

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Lymphoma Statistics December 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on